Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Toronto
Clinical trial register · Canada

Clinical Trials in Toronto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6531 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6531
Studies in scope
all four open statuses
3507
Recruiting now
open to new participants
889
Lead sponsors
across recruiting studies
Top sites
Toronto 47 Montreal 32 Ottawa 12 Calgary 10 Vancouver 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Health Network, Toronto344 Sunnybrook Health Sciences Centre136 AstraZeneca119 The Hospital for Sick Children78 Centre for Addiction and Mental Health70 Clear sponsor filter
Site location
Toronto47 Montreal32 Ottawa12 Calgary10 Vancouver9
All 31 locations
Target enrolment
to

Trials with a site in Toronto

47 of 6531 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
GlaxoSmithKline
Phase 3
690
Toronto, Montreal
2026-09-08
Recruiting
GlaxoSmithKline
Phase 3
800
Toronto, Montreal
2026-07-27
Recruiting
GlaxoSmithKline
Phase 1/2
64
Toronto, Montreal
2026-06-22
Recruiting
GlaxoSmithKline
Phase 3
450
Toronto, Montreal
2026-06-18
Not yet open
GlaxoSmithKline
Phase 1/2
49
Toronto
2026-06-12
Recruiting
GlaxoSmithKline
Phase 3
600
Toronto, Montreal
2026-06-04
Recruiting
GlaxoSmithKline
Phase 1
97
Toronto, Montreal
2026-03-23
Recruiting
GlaxoSmithKline
Phase 1/2
54
Toronto, Montreal
2026-02-10
Recruiting
GlaxoSmithKline
Phase 3
450
Calgary, Toronto, Montreal
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1
83
Ottawa, Toronto
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1/2
47
Hamilton, Toronto, Montreal
2025-10-20
Recruiting
GlaxoSmithKline
Phase 2
220
Ottawa, Peterborough, Toronto, Greenfield Park, Sherbrooke
2025-08-14
Recruiting
GlaxoSmithKline
Phase 3
420
Ottawa, Toronto, Montreal
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
Edmonton, Vancouver, London, Toronto
2025-08-06
Recruiting
GlaxoSmithKline
Phase 3
981
Richmond, Ajax, Toronto, Windsor, Saint-Charles-Borromée, Sherbrooke, Saskatoon
2025-06-20
Recruiting
GlaxoSmithKline
Phase 1/2
85
Toronto, Montreal
2025-06-12
Recruiting
GlaxoSmithKline
Phase 1/2
451
Calgary, Toronto, Montreal, Sherbrooke
2025-06-11
Recruiting
GlaxoSmithKline
Phase 2
80
Calgary, Toronto
2025-06-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
Vancouver, Toronto, Montreal
2025-03-04
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Vancouver, Toronto, Montreal
2025-02-28
Active, closed
GlaxoSmithKline
Phase 2
307
Kelowna, Ajax, London, Toronto, Windsor, Trois-Rivières
2025-02-10
Active, closed
GlaxoSmithKline
Phase 1
86
London, Toronto, Montreal
2024-12-11
Active, closed
GlaxoSmithKline
Phase 2
283
Calgary, Ottawa, Toronto, Montreal
2024-11-11
Recruiting
GlaxoSmithKline
Phase 1
845
Hamilton, Ottawa, Toronto, Montreal, Sherbrooke
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Calgary, New Westminster, Vancouver, London, Toronto, Montreal, Terrebonne
2024-09-27
Active, closed
GlaxoSmithKline
Phase 2
153
Ottawa, Toronto, Montreal, Québec
2024-09-17
Recruiting
GlaxoSmithKline
Phase 1
675
Ottawa, Toronto, Montreal
2024-07-02
Recruiting
GlaxoSmithKline
Phase 3
864
Greater Sudbury, Hamilton, Toronto, Montreal
2024-03-21
Active, closed
GlaxoSmithKline
Phase 4
336
Calgary, Winnipeg, Toronto
2024-03-20
Active, closed
GlaxoSmithKline
Phase 2
316
Calgary, Edmonton, Toronto, Montreal
2023-11-14
Active, closed
GlaxoSmithKline
Phase 1/2
42
Edmonton, Toronto, Montreal
2023-10-24
Recruiting
GlaxoSmithKline
Phase 3
892
Edmonton, Halifax, Ottawa, Toronto, Montreal
2023-08-01
Active, closed
GlaxoSmithKline
Phase 2
154
Ottawa, Toronto, Montreal, Sherbrooke
2023-04-03
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Calgary, Toronto
2023-01-02
Recruiting
GlaxoSmithKline
Phase 3
109
Ottawa, Toronto
2022-09-06
Active, closed
GlaxoSmithKline
Phase 3
3,038
Vancouver, Victoria, Halifax, Truro, Toronto, Mirabel, Québec, Sherbrooke
2022-08-10
Active, closed
GlaxoSmithKline
Phase 3
163
Toronto
2022-07-14
Active, closed
GlaxoSmithKline
Phase 1
152
Ottawa, Toronto
2022-03-22
Active, closed
GlaxoSmithKline
Phase 2
360
Calgary, Victoria, Toronto, Montreal, Québec
2021-12-14
Active, closed
GlaxoSmithKline
Phase 1/2
30
Toronto
2021-07-29
Active, closed
GlaxoSmithKline
Phase 3
40
Calgary, Toronto, Montreal, Québec
2021-06-28
Recruiting
GlaxoSmithKline
Phase 2
37
Kelowna, Toronto, Montreal
2021-04-16
Active, closed
GlaxoSmithKline
Phase 3
242
Edmonton, Toronto
2020-07-14
Active, closed
GlaxoSmithKline
Phase 1
107
Ottawa, Toronto
2020-06-25
Active, closed
GlaxoSmithKline
Phase 1/2
25
Vancouver, Toronto
2019-11-26
Active, closed
GlaxoSmithKline
Phase 1/2
208
Vancouver, Halifax, Toronto
2019-10-07
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Toronto, Montreal
2018-05-03
Rows per page Showing 1–47 of 47
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-canada/city/toronto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,531 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 47 of those studies with a site in Toronto that also match the filters currently applied.

How many clinical trials are recruiting in Toronto?

25 of the 47 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Toronto), 47 studies
PhaseStudiesRecruitingShare
Phase 214529.8%
Phase 3141029.8%
Phase 1/211623.4%
Phase 17414.9%
Phase 4102.1%

Most active sponsors

Lead sponsors with the most studies (Toronto)
Lead sponsorStudiesRecruiting
GlaxoSmithKline4725
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.